Here’s Why Apellis Pharmaceuticals Fell Today

What happened

Shares of Apellis Pharmaceuticals (NASDAQ: APLS), a clinical-stage biopharmaceutical company, fell on Thursday after Regeneron (NASDAQ: REGN) released top-line data for pozelimab. Investors worried that Apellis’ lead candidate APL-2 won’t be able to compete and hammered the stock 13.6% lower on Thursday.

So what

Today, Regeneron announced successful results for pozelimab, an experimental treatment for a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH). After eight weeks of treatment with the injectible antibody, levels of lactate dehydrogenase (LDH) fell to normal levels for all six patients treated.

Image source: Getty Images.

In September, Apellis began a phase 3 study with APL-2 and PNH patients following a successful six-patient phase 2 trial. In phase 2, Apellis’ candidate also lowered LDH to normal levels, although not quite as low as scores that Regeneron posted for pozelimab.

Now what

Investors should know that APL-2 targets a different part of the immune system than pozelimab. It’s still unclear which approach is better after single-arm studies with small groups from different populations, but we can say that commercial success is far from guaranteed.

If the PNH indication doesn’t work out, though, APL-02 is also in a phase 3 trial with patients losing their sight to geographic atrophy secondary to age-related macular edema (GA). Around 1 million Americans are losing their sight to GA and there aren’t any available treatments to prevent its progression.

10 stocks we like better than Apellis Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Apellis Pharmaceuticals, Inc. wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of December 1, 2019

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

You May Also Like

About the Author: Over 50 Finance